AstronauTx Ltd, a biotechnology firm creating treatments for Alzheimer's Disease and various neurological conditions through enhancement of sleep patterns, announces the hiring of Dr. Michelle Mellion as Chief Medical Officer (CMO) and Deb Gouveia as Vice President of Clinical Operations and Development Strategy.
Dr. Mellion is an experienced neurologist and clinical development head, offering over twenty years of expertise in both academia and the biotechnology field. She possesses a robust history of promoting groundbreaking treatments for neurological and rare conditions, such as neuromuscular diseases.
Recently, Dr. Mellion served as Chief Medical Officer at PepGen and EveryONE Medicines, directing clinical development initiatives for oligonucleotide therapies and personalized medicines for extremely rare diseases.
Also Read: Five Iconic European Brands that Shape Everyday Life Worldwide
In the initial phases of her career, she worked at Biogen, Vertex Pharmaceuticals, and Fulcrum Therapeutics, aiding in initiatives related to remyelination, pain, and facioscapulohumeral muscular dystrophy (FSHD).
Also Read: Europe's Most Business-Friendly Nations to Start New Enterprises
As CMO at AstronauTx, Dr. Mellion will oversee clinical strategy and development efforts, collaborating closely with executive and leadership teams to progress its pipeline into clinical trials.
Gouveia has over 25 years of experience in creating and managing clinical operations, regulatory affairs, quality, and development frameworks within emerging biotechnology firms.
Jane Rhodes, Chief Executive Officer at AstronauTx says, “Michelle’s appointment marks an important milestone for AstronauTx. Her track record in advancing therapies for neurological and rare diseases aligns strongly with our ambition to develop transformative treatments targeting sleep architecture. As we build out our clinical capabilities and progress our pipeline, the appointments of Michelle and Deb strengthen the expertise driving our transition into clinical‑stage development.”
Also Read: Europe 2026: From Fast Growth to Resilient Startup Innovation
Dr. Michelle Mellion, Chief Medical Officer at AstronauTx adds, “AstronauTx represents a rare opportunity to help define an entirely new therapeutic category at the intersection of sleep biology and neurodegenerative disease. The Company’s innovative approach to leveraging slow-wave sleep modulation as a potential disease-modifying strategy is both scientifically compelling and strategically differentiated, and I am excited to work with the team to advance these programmes into clinical development.”